AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3308720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (80‐100 mg/kg/day)
Number of subjects: 40
Study 3308720 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin (6 mg/kg/day)
Number of subjects: 40
Study 3308720 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 40
Study 28714658 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive shoulder-neck exercise program (6 weeks)
Number of subjects: 72
Study 28714658 — intervention group
Group type: COMPARATOR
Intervention: Traditional physiotherapy
Number of subjects: 72
Study 27881145 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic intervention by a social worker to support informal caregivers
Number of subjects: 0
Study 24633406 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of clopidogrel maintenance therapy over four weeks
Number of subjects: 782
Study 24633406 — intervention group
Group type: COMPARATOR
Intervention: Abrupt discontinuation of clopidogrel therapy after continued therapy for an additional four weeks
Number of subjects: 782
Study 24633406 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual tapering of clopidogrel maintenance therapy
Number of subjects: 782
Study 24633406 — intervention group
Group type: COMPARATOR
Intervention: Abrupt discontinuation of clopidogrel therapy
Number of subjects: 782
Study 23732173 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy guided by stroke volume variation, optimized global end-diastolic volume index, mean arterial pressure, and cardiac index (SG)
Number of subjects: 100
Study 23732173 — intervention group
Group type: COMPARATOR
Intervention: Algorithm based on mean arterial pressure and central venous pressure (CG)
Number of subjects: 100
Study 19969446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium via Respimat (5microg)
Number of subjects: 134
Study 19969446 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium via HandiHaler (18microg)
Number of subjects: 134
Study 18808445 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone-3-glucuronide (NX3G) 0.16 mg/kg
Number of subjects: 15
Study 18808445 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.05 mg/kg
Number of subjects: 15
Study 18808445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16192723 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 1219
Study 16192723 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 1219
Study 14516877 — intervention group
Group type: EXPERIMENTAL
Intervention: trapidil 100 mg 3 times daily
Number of subjects: 1743
Study 14516877 — intervention group
Group type: COMPARATOR
Intervention: Control (no trapidil)
Number of subjects: 1743
Study 10232717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg x kg(‐1))
Number of subjects: 15
Study 10232717 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.3 mg x kg(‐1))
Number of subjects: 15
Study 8912772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA)
Number of subjects: 21
Study 8912772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA) at 4:00 A.M.
Number of subjects: 21
Study 8912772 — intervention group
Group type: COMPARATOR
Intervention: Alveolar tissue eosinophils
Number of subjects: 21
Study 1748136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 5 mg
Number of subjects: 12
Study 1748136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 12
Study 1748136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 15 mg
Number of subjects: 12
Study 1748136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg
Number of subjects: 12
Study 1748136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg
Number of subjects: 12
Study 1748136 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 12
Study 6805361 — intervention group
Group type: COMPARATOR
Intervention: 0 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Number of subjects: 80
Study 6805361 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Number of subjects: 80
Study 6805361 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Number of subjects: 80
Study 6805361 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg morphine in 6 ml saline
Number of subjects: 80
Study 31067138 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Consolidative Therapy (LCT)
Number of subjects: 49
Study 31067138 — intervention group
Group type: COMPARATOR
Intervention: Maintenance Therapy or Observation (MT/O)
Number of subjects: 49
Study 28849623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron sucrose
Number of subjects: 192
Study 28849623 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate
Number of subjects: 192
Study 27892820 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led educational programme 'Listen Up'
Number of subjects: 7709
Study 27892820 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 7709
Study 24717794 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA‐AQ (triamcinolone acetonide aqueous nasal spray, 110 μg for 2-11 years old or 220 μg for 6-11 years old)
Number of subjects: 140
Study 24717794 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA‐AQ (triamcinolone acetonide aqueous nasal spray)
Number of subjects: 140
Study 24717794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 22266992 — intervention group
Group type: EXPERIMENTAL
Intervention: High Concentrate/High Gain (HC/HG) diet
Number of subjects: 12
Study 22266992 — intervention group
Group type: COMPARATOR
Intervention: High Forage/Low Gain (HF/LG) diet
Number of subjects: 12
Study 18996033 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mL of 4% articaine/HCl injected into the buccal vestibule
Number of subjects: 71
Study 18996033 — intervention group
Group type: COMPARATOR
Intervention: Routine administration with additional palatal injection
Number of subjects: 71
Study 17617286 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. administered at one of three doses (0.25 pg/150 IU, 0.4 pg/150 IU, or 0.6 pg/150 IU) with frequency subgroups of QW or Q2W.
Number of subjects: 91
Study 17617286 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. QW or Q2W
Number of subjects: 91
Study 15359376 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole (1st day: 3 x 384 mg, 2nd day: 4 x 384 mg, 3rd day: 3 x 384 mg, 4th day: 2 x 384 mg, 5th day: 1 x 384 mg)
Number of subjects: 20
Study 15359376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11574936 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with vaginal balls
Number of subjects: 37
Study 11574936 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training without vaginal balls
Number of subjects: 37
Study 9609408 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (group 1) with 500 ml of blood withdrawn and 6% hydroxyethyl starch infused
Number of subjects: 16
Study 9609408 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2) without haemodilution and autologous blood transfusion
Number of subjects: 16
Study 7820060 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN)
Number of subjects: 69
Study 7820060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 69
Study 7820060 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CdA)
Number of subjects: 69
Study 3403476 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 g NaCl per 100 ml water (Na-R)
Number of subjects: 6
Study 3403476 — intervention group
Group type: COMPARATOR
Intervention: Tap water (H2O-R)
Number of subjects: 6
Study 3403476 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-R
Number of subjects: 6
Study 3403476 — intervention group
Group type: COMPARATOR
Intervention: H2O-R
Number of subjects: 6
Study 2050460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 0
Study 2050460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 0
Study 2050460 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 2050460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 339773 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate with polyethylene glycol as a solvent
Number of subjects: 0
Study 30886334 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-predicted triglycerides
Number of subjects: 367703
Study 30886334 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-predicted log-transformed IL-6
Number of subjects: 367703
Study 30886334 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically-predicted log-transformed CRP
Number of subjects: 367703
Study 30886334 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of heart disease
Number of subjects: 367703
Study 30886334 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD genetic risk score
Number of subjects: 367703
Study 31050233 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotic treatment
Number of subjects: 234
Study 31050233 — intervention group
Group type: COMPARATOR
Intervention: Declined participation for LAI antipsychotic treatment
Number of subjects: 234
Study 31050233 — intervention group
Group type: COMPARATOR
Intervention: Other reasons for declining participation
Number of subjects: 234
Study 28720132 — intervention group
Group type: EXPERIMENTAL
Intervention: IND/GLY 110/50 μg q.d.
Number of subjects: 4389
Study 28720132 — intervention group
Group type: COMPARATOR
Intervention: LABA + ICS
Number of subjects: 4389
Study 28720132 — intervention group
Group type: COMPARATOR
Intervention: LABA or LAMA
Number of subjects: 4389
Study 25890225 — intervention group
Group type: EXPERIMENTAL
Intervention: OpalSeal sealant application
Number of subjects: 36
Study 24171685 — intervention group
Group type: COMPARATOR
Intervention: Above-elbow cast (AEC) for 6 weeks
Number of subjects: 127
Study 24171685 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of AEC followed by 3 weeks of below-elbow cast (BEC)
Number of subjects: 127
Study 24171685 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of AEC followed by 3 weeks of BEC
Number of subjects: 127
Study 21883109 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual gait speed
Number of subjects: 217
Study 19626471 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumented lumbar spinal fusion
Number of subjects: 94
Study 19626471 — intervention group
Group type: COMPARATOR
Intervention: Non-instrumented lumbar spinal fusion
Number of subjects: 94
Study 17450066 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin treatment
Number of subjects: 55
Study 17450066 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 55
Study 15870668 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine supplement (0.6 g.kg ‐1 .d ‐1)
Number of subjects: 20
Study 15870668 — intervention group
Group type: COMPARATOR
Intervention: Control group (no glutamine supplement)
Number of subjects: 20
Study 11576569 — intervention group
Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception (three courses of therapy) along with information
Number of subjects: 411
Study 11576569 — intervention group
Group type: COMPARATOR
Intervention: Information only about emergency contraception
Number of subjects: 411
Study 9561995 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated care (admission to a nonintensive care unit and day 3 hospital discharge without noninvasive testing)
Number of subjects: 471
Study 9561995 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated care
Number of subjects: 471
Study 7880409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac gel
Number of subjects: 12
Study 7880409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3066339 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 infusion (4 to 12 hours daily)
Number of subjects: 0
Study 3066339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31705683 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group receiving drops and lozenges containing L. reuteri (ATCC PTA 5289 & DSM 17938)
Number of subjects: 0
Study 31705683 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving placebo products
Number of subjects: 0
Study 30301473 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (combined aerobic and resistance exercise)
Number of subjects: 32
Study 30301473 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 32
Study 28082098 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technology (3DP)
Number of subjects: 42
Study 28082098 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 25554404 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg orally every other day for the first month and once daily thereafter, in addition to background therapy with ACEI or ARB.
Number of subjects: 42
Study 25554404 — intervention group
Group type: COMPARATOR
Intervention: Placebo, in addition to background therapy with ACEI or ARB.
Number of subjects: 42
Study 23675790 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit rehabilitation
Number of subjects: 28
Study 23675790 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation
Number of subjects: 28
Study 23675790 — intervention group
Group type: COMPARATOR
Intervention: Wii Fit rehabilitation and Traditional rehabilitation
Number of subjects: 28
Study 21597204 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular apical pacing (RVA)
Number of subjects: 103
Study 21597204 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular septal pacing (RVS)
Number of subjects: 103
Study 21597204 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study 19862936 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (200 mg twice a day)
Number of subjects: 17
Study 19862936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16760868 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA+GA
Number of subjects: 80
Study 16760868 — intervention group
Group type: COMPARATOR
Intervention: GA
Number of subjects: 80
Study 15317711 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse diode laser (810 nm)
Number of subjects: 16
Study 15317711 — intervention group
Group type: COMPARATOR
Intervention: Conventional argon laser (514 nm)
Number of subjects: 16
Study 10870744 — intervention group
Group type: EXPERIMENTAL
Intervention: NMDA-receptor antagonists (e.g., ketamine, dextromethorphan, memantine, amantadine)
Number of subjects: 0
Study 10870744 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (e.g., methadone, dextropropoxyphene, ketobemidone)
Number of subjects: 0
Study 8894195 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 74
Study 1814876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 18
Study 1814876 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study 6240470 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 125
Study 6240470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 125
Study 6240470 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxolinic acid
Number of subjects: 125
Study 6240470 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 125
Study 28559003 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV-13
Number of subjects: 155
Study 28559003 — intervention group
Group type: COMPARATOR
Intervention: PPV-23
Number of subjects: 155
Study 28559003 — intervention group
Group type: COMPARATOR
Intervention: PPV-23-pre-vaccinated
Number of subjects: 155
Study 27871702 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse closing loop
Number of subjects: 36
Study 27871702 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladanyi spring
Number of subjects: 36
Study 27871702 — intervention group
Group type: COMPARATOR
Intervention: Direct skeletal anchorage system
Number of subjects: 36
Study 27871702 — intervention group
Group type: COMPARATOR
Intervention: Indirect skeletal anchorage system
Number of subjects: 36
Study 25784663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental diabetes
Number of subjects: 699
Study 25784663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental hypertension
Number of subjects: 699
Study 25784663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental obesity (BMI >30 kg/m(2))
Number of subjects: 699
Study 25784663 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental depressive symptoms
Number of subjects: 699
Study 25784663 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclinical binge eating (BE) in parents
Number of subjects: 699
Study 22961092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (UR65), 125 mL once daily for 24 weeks
Number of subjects: 118
Study 22961092 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage, 125 mL once daily for 24 weeks
Number of subjects: 118
Study 20200820 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-pain specific information leaflet
Number of subjects: 174
Study 20200820 — intervention group
Group type: COMPARATOR
Intervention: Leaflet without content regarding back pain (control)
Number of subjects: 174
Study 17997364 — intervention group
Group type: EXPERIMENTAL
Intervention: PDA-based self-monitoring intervention
Number of subjects: 151
Study 16011136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pterygopalatine fossa infiltration with 2 mL of 2% lidocaine and 1:80,000 adrenalin
Number of subjects: 55
Study 16011136 — intervention group
Group type: COMPARATOR
Intervention: Noninjected side
Number of subjects: 55
Study 12970309 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate HRT
Number of subjects: 30
Study 12970309 — intervention group
Group type: COMPARATOR
Intervention: Combined HRT with estradiol valerate and levonorgestrel
Number of subjects: 30
Study 10090355 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g of alcohol
Number of subjects: 40
Study 10090355 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of alcohol
Number of subjects: 40
Study 10090355 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g of alcohol
Number of subjects: 40
Study 10090355 — intervention group
Group type: COMPARATOR
Intervention: 0 g of alcohol (water)
Number of subjects: 40
Study 7772781 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ear occlusion
Number of subjects: 30
Study 7772781 — intervention group
Group type: COMPARATOR
Intervention: Left ear occlusion
Number of subjects: 30
Study 2148502 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP (Lower Body Negative Pressure) at -40 mmHg
Number of subjects: 17
Study 2148502 — intervention group
Group type: EXPERIMENTAL
Intervention: LBPP (Lower Body Positive Pressure)
Number of subjects: 17
Study 2148502 — intervention group
Group type: COMPARATOR
Intervention: LBNP and LBPP in hypertensive patients with LVH
Number of subjects: 17
Study 389338 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 51
Study 389338 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 51
Study 31866081 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraGraft
Number of subjects: 250
Study 31866081 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 250
Study 28514235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous pretreatment)
Number of subjects: 33
Study 28514235 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no ondansetron)
Number of subjects: 33
Study 25901558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT)
Number of subjects: 0
Study 25901558 — intervention group
Group type: COMPARATOR
Intervention: Conventional chest radiography
Number of subjects: 0
Study 24237724 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel (n = 15 per category)
Number of subjects: 60
Study 24237724 — intervention group
Group type: COMPARATOR
Intervention: Non-aloe vera group (n = 15 per category)
Number of subjects: 60
Study 21402559 — intervention group
Group type: EXPERIMENTAL
Intervention: Single stimulation with IM
Number of subjects: 42
Study 21402559 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple stimulation with IM
Number of subjects: 42
Study 21402559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 19097758 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g intravenous dose
Number of subjects: 21
Study 18175079 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-CTA as the primary diagnostic investigation
Number of subjects: 38
Study 18175079 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical clipping of the aneurysm
Number of subjects: 38
Study 15570830 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic (LA) group
Number of subjects: 96
Study 15570830 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 96
Study 15570830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 11837512 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone plus letrozole
Number of subjects: 0
Study 11837512 — intervention group
Group type: COMPARATOR
Intervention: Testosterone plus placebo
Number of subjects: 0
Study 9551674 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF alone (65-250 microg/m2 three times weekly for 6 months)
Number of subjects: 71
Study 9551674 — intervention group
Group type: COMPARATOR
Intervention: Interferon alone (3 mU three times weekly for 6 months)
Number of subjects: 71
Study 9551674 — intervention group
Group type: COMPARATOR
Intervention: Interferon + GM-CSF (3 mU + 250 microg/m2 three times weekly for 6 months)
Number of subjects: 71
Study 9551674 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF treatment
Number of subjects: 71